Abstracts tagged "Patient reported outcomes"

Abstract Number: 0520 • ACR Convergence 2025
Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Stephanie Lee¹, Chadwick Johr², Nora Sandorfi², Ali Dhanaliwala² and Dana DiRenzo², ¹University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Salivary Gland Ultrasound (SGUS) can be useful in the evaluation and management of Sjögren’s Disease (SjD) but its use has been limited to trained…
Abstract Number: 0368 • ACR Convergence 2025
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Hareem Farooq¹, Lesley Jackson¹, Rahima Begum², Gary Cutter², Kenneth Saag³, Jinoos Yazdany⁴ and Maria I. ("Maio") Danila⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF, San Francisco, CA, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Home-based telemedicine is an efficient healthcare delivery approach. A recent randomized clinical trial (RCT) found that in-person visits may be preferred among rheumatology patients.…
Abstract Number: 2435 • ACR Convergence 2025
Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
Victoria Werth¹, Coburn Hobar², Rachana Agrawal³, Miriam Kimel⁴, Mona L. Martin⁴, Julia R. Correll⁴, Jiyoon Choi², Antonia Christodoulou⁵, Laurie Eliason⁶ and Joseph F Merola⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Princeton, ⁴Evidera, Wilmington, NC, ⁵BMS, Princeton, NJ, ⁶Bristol Myers Squibb,, Princeton, NJ, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Deucravacitinib is an oral, selective, allosteric TYK2 inhibitor currently under investigation for the treatment of active discoid and/or subacute cutaneous lupus erythematosus (DLE and…
Abstract Number: 1961 • ACR Convergence 2025
Clinical Utility and Patient Experience of Ultrasound-Guided Synovial Biopsy in Refractory Arthritis: A Case Series from a Secondary Care Center
Maria Beatriz Paredes Romero¹, Elisabet Castañeda Estévez², Martina Steiner³, Marco Algarra- San José³, Ana Valeria Acosta³, Tatiana Cobo-Ibáñez⁴, Isabel De la Cámara³, Ana Victoria Esteban Vázquez⁵, Patricia Richi³, Maria Liz Romero-Bogado³, Laura Trives⁵, Cristina Vergara-Dangond⁴, Jorge palomar-Ramos³ and Santiago Muñoz⁵, ¹Infanta Sofía University Hospital, Madrid, Spain, ²Hospital Universitario Infanta Sofía, Madrid, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain
Background/Purpose: Diagnosing arthritis remains challenging in a subset of patients despite advances in imaging, serological markers, and clinical scoring systems. Ultrasound-guided synovial biopsy (USG-SB) stands…
Abstract Number: 1403 • ACR Convergence 2025
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
Anna Kuhn¹, Magdalena Seng², Björn Christian Frye³, Sebastian Fähndrich³, Lydia Vollmer³, Jacques-eric GOTTENBERG⁴, Florian Kollert⁵, Reinhard Voll⁶ and Stephanie Finzel⁷, ¹¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, Freiburg, Germany, ²¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; ²University Medical Center, Department of Radiology and Nuclear medicine, Basel, Switzerland, Freiburg, Germany, ³³University Medical Center, Department of Pulmonology, Freiburg, Germany, Freiburg, Germany, ⁴Hautepierre Hospital, STRASBOURG, Alsace, France, ⁵¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern; Switzerland Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶University Medical Center Freiburg, Freiburg, Germany, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Background/Purpose: About 70% of patients with primary Sjögren's disease (pSjD) suffer from fatigue. Fatigue is associated with functional deficits(1), leading to anxiety, depression and reduced…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0367 • ACR Convergence 2025
Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
Hannah Concannon¹, Kai Sun², Jennifer Rogers³, Megan Clowse⁴, Rachel Randell², Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Nathaniel Harris⁶, Amanda Eudy⁷ and Rebecca Sadun², ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University, Raleigh, NC
Background/Purpose: Medication adherence poses a challenge for patients with SLE, especially younger patients, who often experience both more active disease and more intensive treatments than…
Abstract Number: 2426 • ACR Convergence 2025
Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
Sarah Lieber¹, Neha Nagpal¹, Julia Nguyen², Ashley Chung², Dongmei Sun¹, Iris Navarro-Millan³, M. Carrington Reid⁴ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: The benefits of physical activity are well established in older adults in the general population. Among older adults with rheumatic and musculoskeletal diseases, including…
Abstract Number: 1733 • ACR Convergence 2025
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Adela Francis-Malave¹, Terri Laufer², Joshua Baker³, Kyra Sacksith⁴, Melissa Batson⁴ and Sokratis Apostolidis³, ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: While immune-related adverse events (irAEs) are a commonly reported complication of immune checkpoint inhibitor (ICI) therapy, factors associated with their development remain poorly defined.…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…
Abstract Number: 1085 • ACR Convergence 2025
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Sri Lakshmi Sathiyaseelan¹, Sandeep Kansurkar², Kavita Krishna³ and Varsha Bhatt⁴, ¹Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India, ²Bharti vidyapeeth (DTU) Medical College, Pune, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ⁴Department of Clinical Immunology and Rheumatology, Bharati Vidyapeeth (Deemed To Be) University Medical College,Pune, Pune, Maharashtra, India
Background/Purpose: Rheumatoid arthritis presents with multiple joint pains and it is traditionally, examined by the clinicians. The utility of patient self‐joint counts has become an…
Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Jérôme Avouac¹, Neil Betteridge², Karen Bevers³, Gerd Burmester⁴, Roberto Caporali⁵, Ouafia Bouzid⁶, Thomas Debray⁶, Carole Van der Donckt⁶, James Galloway⁷, Susana Romero-Yuste⁸ and Patrick Verschueren⁹, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²Neil Betteridge Associates, London, United Kingdom, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁶Alfasigma S.p.A., Bologna, Italy, ⁷King's College London, London, United Kingdom, ⁸University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
Abstract Number: 0366 • ACR Convergence 2025
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
Fernanda M. Garcia-Garcia¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Gabriel P. Castro-Cruz³, Carlos I. Estrada-Anguiano³, Jennifer Garcia-Bravo³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado¹ and Janett C. Riega-Torres⁴, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health conditions are frequent in patients with rheumatic diseases and can impact daily function and quality of life. Factors such as chronic inflammation…
Abstract Number: 0456 • ACR Convergence 2024
Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Yujie Su², Cassie Clinton³, David Curtis⁴, Laura Stradford⁵, Patrick Zueger⁶, William Benjamin Nowell⁷, Pankaj Patel⁸, Esteban Rivera⁹, Kelly Gavigan⁴, Shilpa Venkatachalam¹⁰ and Fenglong Xie³, ¹FASTER Medicine, Hoover, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶AbbVie Inc, North Chicago, IL, ⁷Regeneron, New York, NY, ⁸AbbVie Inc., North Chicago, IL, ⁹Global Healthy Living Foundation, Long Island City, NY, ¹⁰Global Healthy Living Foundation, New York, NY
Background/Purpose: Digital health technology to collect electronic patient reported outcomes (ePRO) and biosensor data are increasingly used to generate real-world data in pharmacoepidemiology. However, the…

« Previous Page
1
…
5
6
7
8
9
…
50
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].